@modic123 VCs are often hyper-bulls. But more than that, private investing doesn't often translate well to public investing, different skillsets
Early stage VCs should book the win and move on. What we are seeing is VCs tempted to stay on and see further upside post-IPO
Giving a management update internally on GG tomorrow. We’re getting super close to launch plans. Can’t wait till we can announce concrete details publicly and everyone can see what we’ve secretly been working on
@adventuresinfi I like the idea behind this company, massive tailwinds, large TAM
However doesn't seem to be a moat. Other tele-health companies can easily step into this space with enough $$$
Also their App/online reviews are also notoriously bad, which could hint at low customer retention
$SPCE folks, the S-3 was filed on 5/28 and just went effective today. Shouldn't have been a big surprise for people. Morgan Stanley also highlighted it on 6/2. Wonder if Social Capital is selling shares related to private warrant exercise.
@dagetz Unsure at the moment but it would be only important to them if it adds to their space tourism & point to point travel plans
At this time, $SPCE goes to the height required by NASA/US Military to classify as 'space' - customers will certainly earn astronaut wings at this level
Congratulations to Branson on the team. This really was a historical moment - Chamath outlines the implications below..
Interesting to see how $SPCE reacts at open
1/ People misunderstand space and its implications. Since the Apollo project, focusing on space has allowed engineers and scientists to push the boundaries of the possible.
A fascinating event - Richard Branson attempts to head into space tomorrow to take the lead in the billionaire space race, and the kickstart commercial flights for $SPCE
11 July, 9am ET
Livestream is here, I'll be tuning in:
https://t.co/4DiicUONHQ
1/ $ABCL now below IPO price and then some. No support really, but any news would stop the bleeding
I suspect investors are pricing in lower Bamlanivimab revenues, and the uncertainty of 1404
1404 remains on target on timeline as it is going through accelerated clinical trials
@BogardGreedy $20 was short term support, if consolidation around $19-20, that would be good for the stock in the near future. If not, it is a bit of a falling knife at the moment with no catalysts
I missed this but this is a big deal
$AMRS "first major license in pharma"
Good to see the company has bandwidth to explore its TAM outside of consumer products
https://t.co/StURzuZjl4